RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Clinical trial NCT07030569 · RECRUITING

Trial details

NCT number: NCT07030569
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Status: RECRUITING
Study type: OBSERVATIONAL

Radiomic Radiomics Breast Cancer Metastatic Breast Cancer Stage IV Breast Carcinoma Breast Neoplasms Breast Cancer Breast Cancer With Bone Metastasis Breast Cancer With Metastatic Bone Disease Trastuzumab HER2 HER2 + Breast Cancer

Start date: 2024-02-01
Primary completion: 2027-01-01
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.